Troglitazone: the discovery and development of a novel therapy for the treatment of Type 2 diabetes mellitus (Q34977225)

5 August 2017

1 reference

title

Troglitazone: the discovery and development of a novel therapy for the treatment of Type 2 diabetes mellitus (English)

1 reference

5 August 2017

0 references

Janice C Parker

1

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

Advanced Drug Delivery Reviews

5 August 2017

published in

1 reference

5 August 2017

volume

54

1 reference

5 August 2017

issue

9

1 reference

5 August 2017

page(s)

1173-1197

1 reference

Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: a balanced overview

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Determinants for the progression from impaired glucose tolerance to non-insulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Inferences and implications. Do results from the Diabetes Control and Complications Trial apply in NIDDM?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingd

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Oral hypoglycemic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Pharmacologic therapy for type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Sulfonylureas in NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57).

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

1 reference

7 January 2021

Lactic acidosis in patients with diabetes treated with metformin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

1 reference

7 January 2021

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

1 reference

7 January 2021

Inhibition of hepatic gluconeogenesis by metformin. Synergism with insulin.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Metabolic effects of metformin in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Mechanism by which metformin reduces glucose production in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Acarbose: its role in the treatment of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Studies on antidiabetic agents. II. Synthesis of 5-[4-(1-methylcyclohexylmethoxy)-benzyl]thiazolidine-2,4-dione (ADD-3878) and its derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Role of oxidized low density lipoprotein in atherogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Endogenous antioxidants and lipoprotein oxidation

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

The effect of alpha-tocopherol supplementation on LDL oxidation. A dose-response study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Troglitazone increases the resistance of low density lipoprotein to oxidation in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Characterization of CS-045, a new oral antidiabetic agent, II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Metabolic effects of troglitazone on fat-induced insulin resistance in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Thiazolidinediones (AD-4833 and CS-045) improve hepatic insulin resistance in streptozotocin-induced diabetic rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Antidiabetic agent englitazone enhances insulin action in nondiabetic rats without producing hypoglycemia

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

The effect of CP 68,722, a thiozolidinedione derivative, on insulin sensitivity in lean and obese Zucker rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Suppression of hepatic gluconeogenesis in long-term Troglitazone treated diabetic KK and C57BL/KsJ-db/db mice

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Section Review: Oncologic, Endocrine & Metabolic: Thiazolidinediones

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Improvement in the gastrointestinal absorption of troglitazone when taken with, or shortly after, food

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Clinical pharmacokinetics of troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Lack of effect of type II diabetes on the pharmacokinetics of troglitazone in a multiple-dose study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

High-performance frontal analysis for the study of protein binding of troglitazone (CS-045) in albumin solution and in human plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Meta-analysis of steady-state pharmacokinetics of troglitazone and its metabolites

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

A pilot clinical trial of a new oral hypoglycemic agent, CS-045, in patients with non-insulin dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Mechanisms and clinical effects of thiazolidinediones

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Troglitazone use in insulin-treated type 2 diabetic patients. The Troglitazone Insulin Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Long-term effects of troglitazone: open-label extension studies in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Troglitazone in combination with sulphonylurea improves glycaemic control in Type 2 diabetic patients inadequately controlled by sulphonylurea therapy alone. Troglitazone Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Troglitazone combination therapy in obese type 2 diabetic patients poorly controlled with alpha-glucosidase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Diabetic dyslipidaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Plasma triglyceride as a risk factor for coronary heart disease. The epidemiologic evidence and beyond

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Antihypertensive effects of CS-045 treatment in obese Zucker rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Troglitazone action is independent of adipose tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Banting lecture 1988. Role of insulin resistance in human disease

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Hypertension in diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Etiology and prevalence of hypertension in diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Inhibitory action of insulin-sensitizing agents on calcium channels in smooth muscle cells from resistance arteries of guinea-pig

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Effects of troglitazone on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Troglitazone improves endothelial dysfunction in patients with insulin resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Troglitazone Improves Defects in Insulin Action, Insulin Secretion, Ovarian Steroidogenesis, and Fibrinolysis in Women with Polycystic Ovary Syndrome1

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Troglitazone (CS-045) inhibits beta-cell proliferation rate following stimulation of insulin secretion in HIT-T 15 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Effect of Troglitazone on B Cell Function, Insulin Sensitivity, and Glycemic Control in Subjects with Type 2 Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Hepatic dysfunction associated with troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Troglitazone-induced hepatic failure leading to liver transplantation. A case report

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Fatal hepatotoxicity associated with troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

An autopsy case of troglitazone-induced fulminant hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

In vitro studies on the action of CS-045, a new antidiabetic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Thiazolidinediones inhibit lipoprotein lipase activity in adipocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Free fatty acids and pathogenesis of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

The steroid and thyroid hormone receptor superfamily

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

The Molecular Pharmacology of SERMs

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

PPAR gamma and the treatment of insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Peroxisome proliferator-activated receptor (PPAR) gamma agonists for diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Thiazolidinediones: a comparative review of approved uses

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Thiazolidinediones: an update.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

Peroxisome Proliferator-activated Receptor α Activators Improve Insulin Sensitivity and Reduce Adiposity

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

[[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

The new antidiabetic drug MCC-555 acutely sensitizes insulin signaling in isolated cardiomyocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

L-764406 is a partial agonist of human peroxisome proliferator-activated receptor gamma. The role of Cys313 in ligand binding

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900093-5

7 January 2021

10.1016/S0169-409X(02)00093-5

Identifiers

DOI

1 reference

5 August 2017

1 reference